Search

Search Constraints

You searched for: Author/Creator Rustin, Gordon

Search Results

1. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (January 2017)

2. Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment. Issue 3 (1st March 2014)

3. Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. (October 2019)

4. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Issue 9 (30th October 2018)

5. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Issue 12 (8th April 2016)

6. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Issue 11 (November 2016)

9. Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer. Issue 4 (1st April 2011)

10. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. (March 2022)